Arax Advisory Partners’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.1M | Buy |
12,159
+8,377
| +221% | +$4.02M | 0.04% | 425 |
|
|
2026
Q1 | $1.86M | Sell |
3,782
-2,577
| -41% | -$1.4M | 0.05% | 288 |
|
|
2025
Q4 | $3.68M | Sell |
6,359
-5,352
| -46% | -$3.03M | 0.11% | 153 |
|
|
2025
Q3 | $5.68M | Buy |
11,711
+9,046
| +339% | +$4.21M | 0.08% | 203 |
|
|
2025
Q2 | $1.26M | Buy |
2,665
+19
| +0.7% | +$7.94K | 0.06% | 215 |
|
|
2025
Q1 | $1.32M | Sell |
2,646
-1,178
| -31% | -$638K | 0.08% | 149 |
|
|
2024
Q4 | $1.99M | Buy |
3,824
+1,368
| +56% | +$752K | 0.13% | 110 |
|
|
2024
Q3 | $1.52M | Sell |
2,456
-24
| -1% | -$14.2K | 0.14% | 85 |
|
|
2024
Q2 | $1.37M | Buy |
2,480
+195
| +9% | +$112K | 0.13% | 91 |
|
|
2024
Q1 | $1.33M | Sell |
2,285
-39
| -2% | -$21.9K | 0.14% | 84 |
|
|
2023
Q4 | $1.23M | Buy |
2,324
+118
| +5% | +$57.1K | 0.14% | 83 |
|
|
2023
Q3 | $1.12M | Buy |
2,206
+1,250
| +131% | +$666K | 0.14% | 81 |
|
|
2023
Q2 | $499K | Buy |
956
+13
| +1% | +$7.01K | 0.06% | 115 |
|
|
2023
Q1 | $543K | Buy |
943
+5
| +0.5% | +$2.82K | 0.07% | 107 |
|
|
2022
Q4 | $516K | Buy |
938
+66
| +8% | +$35K | 0.07% | 106 |
|
|
2022
Q3 | $442K | Sell |
872
-45
| -5% | -$25.2K | 0.07% | 99 |
|
|
2022
Q2 | $498K | Sell |
917
-47
| -5% | -$25.9K | 0.08% | 94 |
|
|
2022
Q1 | $569K | Buy |
964
+150
| +18% | +$86.2K | 0.08% | 95 |
|
|
2021
Q4 | $543K | Sell |
814
-3
| -0.4% | -$1.87K | 0.07% | 104 |
|
|
2021
Q3 | $467K | Sell |
817
-14
| -2% | -$7.68K | 0.06% | 103 |
|
|
2021
Q2 | $419K | Buy |
+831
| New | +$392K | 0.06% | 121 |
|
|
2020
Q4 | $430K | Sell |
923
-128
| -12% | -$60K | 0.06% | 100 |
|
|
2020
Q3 | $464K | Buy |
1,051
+302
| +40% | +$125K | 0.08% | 89 |
|
|
2020
Q2 | $271K | Buy |
749
+243
| +48% | +$81.5K | 0.05% | 121 |
|
|
2020
Q1 | $143K | Sell |
506
-12
| -2% | -$3.78K | 0.03% | 186 |
|
|
2019
Q4 | $168K | Sell |
518
-135
| -21% | -$40.9K | 0.05% | 180 |
|
|
2019
Q3 | $190K | Buy |
653
+202
| +45% | +$57.8K | 0.06% | 160 |
|
|
2019
Q2 | $132K | Buy |
+451
| New | +$124K | 0.04% | 191 |
|
|
2018
Q4 | $124K | Buy |
555
+55
| +11% | +$12.9K | 0.05% | 160 |
|
|
2018
Q3 | $122K | Sell |
500
-107
| -18% | -$24.6K | 0.05% | 171 |
|
|
2018
Q2 | $125K | Buy |
607
+169
| +39% | +$35.9K | 0.05% | 132 |
|
|
2018
Q1 | $90K | Sell |
438
-333
| -43% | -$69.9K | 0.05% | 149 |
|
|
2017
Q4 | $146K | Buy |
771
+2
| +0.3% | +$383 | 0.06% | 121 |
|
|
2017
Q3 | $145K | Buy |
769
+13
| +2% | +$2.35K | 0.07% | 117 |
|
|
2017
Q2 | $132K | Buy |
756
+299
| +65% | +$50.2K | 0.06% | 130 |
|
|
2017
Q1 | $70K | Buy |
+457
| New | +$69.8K | 0.03% | 164 |
|
Other funds holding TMO
Arax Advisory Partners's TMO Position: Q2 2026 in Review
Arax Advisory Partners increased its Thermo Fisher Scientific (TMO) stake by 221% in Q2 2026, buying an estimated $4.02M and bringing the position to 12,159 shares worth $6.1M. The position accounts for 0.04% of the portfolio, ranked #425.
Arax Advisory Partners first reported a position in TMO in Q1 2017 and has held it in 36 quarters since. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Arax Advisory Partners held 12,159 shares of Thermo Fisher Scientific worth $6.1M as of Q2 2026.
- Arax Advisory Partners bought 8,377 Thermo Fisher Scientific shares in Q2 2026, an estimated $4.02M.
- Thermo Fisher Scientific made up 0.04% of Arax Advisory Partners's portfolio in Q2 2026, its #425 holding.
- Arax Advisory Partners first reported a position in Thermo Fisher Scientific in Q1 2017 and has held it in 36 quarters since.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.